Ketamine Matches ECT for Treatment-Resistant Depression: Clinical and Policy Implications

Ketamine Demonstrated Noninferiority to ECT in Adults With Treatment-Resistant Depression

Recent evidence reviewed in a November 2026 discussion paper confirms that ketamine provides rapid and clinically significant antidepressant effects in adults with treatment-resistant depression (TRD), performing comparably to electroconvulsive therapy (ECT). The review, accessible via OpenAlex, synthesizes data from randomized trials and real-world studies, reporting a number needed to treat (NNT) of 3 within one week and 9 at four weeks post-treatment. These results position ketamine as a viable alternative to ECT, a long-standing gold standard for severe TRD.

Mechanisms of Action and Clinical Context

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, exerts its antidepressant effects through rapid modulation of glutamatergic neurotransmission and downstream synaptic plasticity. Unlike ECT, which induces generalized seizures to elicit neurobiological changes, ketamine acts pharmacologically, typically administered intravenously or intranasally in sub-anesthetic doses. The review notes that ketamine's rapid onset—often within hours—contrasts with the slower response seen with ECT and traditional antidepressants, offering a critical advantage for patients with acute symptom burden or suicidality.

Importantly, the review highlights that ketamine's efficacy is not limited to a single administration: repeated dosing protocols have shown sustained benefit in some patients, though optimal maintenance regimens remain under investigation. This mechanistic difference from ECT may inform patient selection, especially for those unable or unwilling to undergo anesthesia or seizure induction.

Policy, Guideline, and Research Implications

The finding that ketamine is noninferior to ECT for TRD has significant implications for clinical guidelines, insurance coverage, and research investment. ECT is often reserved for the most severe, refractory cases due to its logistical complexity and stigma. Ketamine's comparable efficacy and more favorable adverse event profile—particularly its lower rate of cognitive side effects (25% vs. 32% for ECT)—could support its adoption as a frontline intervention in psychiatric practice.

• Guideline development: Major psychiatric associations may revisit their TRD treatment algorithms, potentially elevating ketamine to a higher tier of recommended interventions.
• Insurance policy: Payers have historically restricted ketamine coverage, citing limited evidence and off-label status. This robust comparative data may prompt reconsideration, especially as more jurisdictions approve esketamine (the S-enantiomer) for TRD.
• Research funding: The review's affirmation of ketamine's efficacy may accelerate investment in trials exploring optimal dosing, long-term safety, and comparative effectiveness in diverse populations.

One non-obvious implication is that ketamine's outpatient administration model could reduce overall healthcare system burden compared to ECT, which typically requires inpatient resources, anesthesia, and post-procedure monitoring. This logistical advantage may be particularly relevant in under-resourced or rural settings.

Risks, Limitations, and Unknowns

Despite its promise, ketamine therapy for TRD is not without risk or unresolved questions. The review notes that while adverse event rates are lower than ECT, ketamine can cause dissociation, transient blood pressure elevation, and, in rare cases, substance misuse. Long-term safety data remain limited, particularly regarding cognitive effects and the potential for dependency with repeated use.

Another critical limitation is the heterogeneity of TRD itself: not all patients respond to ketamine, and predictors of response are still being elucidated. The review underscores the need for careful patient assessment, monitoring, and follow-up, as well as informed consent regarding both knowns and unknowns. Regulatory frameworks for ketamine clinics also vary widely by jurisdiction, raising concerns about standardization and quality assurance.

Looking Forward: Clinical Integration and Future Directions

Ketamine's demonstrated noninferiority to ECT for TRD marks a pivotal moment in psychiatric therapeutics, but its integration into routine care will depend on regulatory, payer, and professional society actions. Ongoing and future studies should focus on comparative effectiveness in real-world settings, strategies for relapse prevention, and the identification of biomarkers to guide personalized treatment selection.

Ultimately, the review calls for an open, informed dialogue between clinicians and patients about the risks and benefits of emerging therapies for TRD. As evidence accumulates, stakeholders—including regulators, insurers, and providers—will need to balance innovation with caution, ensuring that expanded access to ketamine is matched by robust safety and quality oversight.

Authored by Dr. Jamie L. Carter, MD, MSc, Clinical Psychiatrist and Research Editor. How we research: This article was reviewed by Dr. Carter on 2026-11-12, referencing primary data from the OpenAlex-indexed review and related clinical trial registries.